Skip to main content

Table 3 Transplant outcomes for patients that underwent allogeneic stem cell transplantation in the retrospective and prospective study

From: Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

   Neutrophil engraftment Platelet engraftment Grades 2–4 acute GVHD Chronic GVHD at 4 years Relapse at 4 years NRM at 4 years LFS at 4 years OS at 4 years
Retrospective study group (n = 339)
MSDT (n = 99) MRDneg (group A) 98% (95% CI, 96–100%) 98% (95% CI, 94–100%) 9% (95% CI, 3 to 15%) ‡, ## 58% (95% CI, 45 to 71%) 11% (95% CI, 4 to 18%) 16% (95% CI, 7 to 25%) 73% (95% CI, 63 to 83%) 76% (95% CI, 66 to 86%)
MRDpos (group B) 93% (95% CI, 79–100%) £ 93% (95% CI, 79–100%) 7% (95% CI, 0 to 21%) †, # 66% (95% CI, 35 to 97%) 60% (95% CI, 22 to 98%) 7% (95% CI, 0 to 21%) 33% (95% CI, 2 to 64%) 33% (95% CI, 2 to 64%)
Haplo-SCT (n = 240) MRDneg (group C) 99% (95% CI, 99–100%) 99% (95% CI, 97–100%) 36% (95% CI, 29 to 43%) 48% (95% CI, 40 to 56%) 15% (95% CI, 10 to 20%) 14% (95% CI, 9 to 19%) 71% (95% CI, 65 to 77%) 75% (95% CI, 69 to 81%)
MRDpos (group D) 98% (95% CI, 96–100%) 97% (95% CI, 93–100%) 43% (95% CI, 29 to 57%) 70% (95% CI, 56 to 84%) * 19% (95% CI, 5 to 33%) 8% (95% CI, 1 to 15%) 73% (95% CI, 58 to 88%) 75% (95% CI, 60 to 90%)
Prospective study group (n = 340) a
MSDT (n = 82) MRDneg (group E) 98% (95% CI, 95–100%) 98% (95% CI, 94–100%) 10% (95% CI, 2 to 17%) $, $$ 56% (95% CI, 39 to 72%) 7% (95% CI, 0 to 13%) 5% (95% CI, 0 to 11%) 88% (95% CI, 79 to 97%) 94% (95% CI, 87 to 100%)
MRDpos (group F) 95% (95% CI, 85–100%) ££ 95% (95% CI, 85–100%) 5% (95% CI, 0 to 15%) ††, ‡‡ 41% (95% CI, 20 to 62%) 36% (95% CI, 14 to 58%) 16% (95% CI, 0 to 33%) 48% (95% CI, 25 to 71%) 64% (95% CI, 42 to 86%)
Haplo-SCT (n = 258) MRDneg (group G) 99% (95% CI, 99–100%) 99% (95% CI, 99–100%) 28% (95% CI, 21 to 35%) 40% (95% CI, 31 to 49%) 7% (95% CI, 3 to 11%) 18% (95% CI, 12 to 24%) 75% (95% CI, 69 to 81%) 78% (95% CI, 72 to 84%)
MRDpos (group H) 97% (95% CI, 91–100%) 98% (95% CI, 94–100%) 32% (95% CI, 20 to 44%) 73% (95% CI, 52 to 94%) ** 13% (95% CI, 4 to 22%) 7% (95% CI, 0 to 14%) 80% (95% CI, 69 to 91%) 83% (95% CI, 73 to 93%)
  1. The differences in any of the transplant outcomes between the four groups were analyzed with a log-rank test
  2. Abbreviations: GVHD graft-versus-host disease, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, MRD minimal residual disease, MSDT human leukocyte antigen-matched sibling donor transplantation, MRDpos MRD positive, MRDneg MRD negative, Haplo-SCT haploidentical stem cell transplantation
  3. £ P < 0.01 compared with group D
  4. ££ P < 0.05 compared with group D
  5. P < 0.05 compared with group C
  6. ## P < 0.01 compared with group D
  7. P < 0.05 compared with group C
  8. # P < 0.01 compared with group D
  9. *P = 0.980 compared with group B
  10. $ P < 0.01 compared with group G
  11. $$ P < 0.01 compared with group H
  12. †† P < 0.05 compared with group G
  13. ‡‡ P < 0.05 compared with group H
  14. **P = 0.223 compared with group F
  15. aIndicates the transplant outcomes of patients in the prospective study are listed as chronic GVHD, relapse, NRM, LFS and OS at 2 years